Collegium Pharmaceutical, Inc. Cost, Amortization
Collegium Pharmaceutical, Inc. (COLL) reported Cost, Amortization of $62.95 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSoldAmortization · last filed 2026-08-06
- Collegium Pharmaceutical, Inc. cost, amortization for the quarter ending 2026-06-30 was $62.95M, a 13.48% increase year-over-year.
- Collegium Pharmaceutical, Inc. cost, amortization for the quarter ending 2026-03-31 was $55.47M, a 0.00% change year-over-year.
- Collegium Pharmaceutical, Inc. cost, amortization for the quarter ending 2025-12-31 was $55.47M, a 0.00% increase year-over-year.
- Collegium Pharmaceutical, Inc. cost, amortization for the quarter ending 2025-09-30 was $55.47M, a 35.96% increase year-over-year.
- Collegium Pharmaceutical, Inc. cost, amortization for fiscal 2025 was $221.89M, a 34.23% increase from fiscal 2024.
- Collegium Pharmaceutical, Inc. cost, amortization for fiscal 2024 was $165.30M, a 13.41% increase from fiscal 2023.
- Collegium Pharmaceutical, Inc. cost, amortization for fiscal 2023 was $145.76M.
- Collegium Pharmaceutical, Inc. cost, amortization for fiscal 2021 was $67.18M, a 10.71% increase from fiscal 2020.
| Period end | Cost, Amortization 3 month | Cost, Amortization 6 month | Cost, Amortization 9 month | Cost, Amortization 12 month |
|---|---|---|---|---|
| 2026-06-30 | $62.95M 10-Q · filed 2026-08-06 | $118.43M 10-Q · filed 2026-08-06 | $173.90M derived: sum of 3 quarters · filed 2026-08-06 | $229.37M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $55.47M 10-Q · filed 2026-05-07 | $110.95M derived: sum of 2 quarters · filed 2026-05-07 | $166.42M derived: sum of 3 quarters · filed 2026-05-07 | $221.89M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $55.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $110.95M derived: sum of 2 quarters · filed 2026-02-26 | $166.42M derived: sum of 3 quarters · filed 2026-08-06 | $221.89M 10-K · filed 2026-02-26 |
| 2025-09-30 | $55.47M 10-Q · filed 2025-11-06 | $110.95M derived: sum of 2 quarters · filed 2026-08-06 | $166.42M 10-Q · filed 2025-11-06 | $221.89M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $55.47M 10-Q · filed 2026-08-06 | $110.95M 10-Q · filed 2026-08-06 | $166.42M derived: sum of 3 quarters · filed 2026-08-06 | $207.22M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $55.47M 10-Q · filed 2026-05-07 | $110.94M derived: sum of 2 quarters · filed 2026-05-07 | $151.75M derived: sum of 3 quarters · filed 2026-05-07 | $186.26M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $55.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $96.27M derived: sum of 2 quarters · filed 2026-02-26 | $130.79M derived: sum of 3 quarters · filed 2026-02-26 | $165.30M 10-K · filed 2026-02-26 |
| 2024-09-30 | $40.80M 10-Q · filed 2025-11-06 | $75.32M derived: sum of 2 quarters · filed 2025-11-06 | $109.83M 10-Q · filed 2025-11-06 | $144.35M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $34.52M 10-Q · filed 2025-08-07 | $69.03M 10-Q · filed 2025-08-07 | $103.55M derived: sum of 3 quarters · filed 2026-02-26 | $139.86M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $34.52M 10-Q · filed 2025-05-08 | $69.03M derived: sum of 2 quarters · filed 2026-02-26 | $105.35M derived: sum of 3 quarters · filed 2026-02-26 | $142.81M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $34.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $70.83M derived: sum of 2 quarters · filed 2026-02-26 | $108.29M derived: sum of 3 quarters · filed 2026-02-26 | $145.76M 10-K · filed 2026-02-26 |
| 2023-09-30 | $36.32M 10-Q · filed 2024-11-07 | $73.78M derived: sum of 2 quarters · filed 2024-11-07 | $111.25M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $37.46M 10-Q · filed 2024-08-08 | $74.93M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $37.47M 10-Q · filed 2024-05-09 | |||
| 2022-09-30 | $37.55M 10-Q · filed 2023-11-07 | $75.05M derived: sum of 2 quarters · filed 2023-11-07 | $93.98M 10-Q · filed 2023-11-07 | $110.77M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $37.50M 10-Q · filed 2023-08-03 | $56.42M 10-Q · filed 2023-08-03 | $73.22M derived: sum of 3 quarters · filed 2023-08-03 | $90.02M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $18.92M 10-Q · filed 2023-05-04 | $35.72M derived: sum of 2 quarters · filed 2023-05-04 | $52.51M derived: sum of 3 quarters · filed 2023-05-04 | $69.31M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $16.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $33.59M derived: sum of 2 quarters · filed 2022-11-03 | $50.39M derived: sum of 3 quarters · filed 2022-11-03 | $67.18M 10-K · filed 2022-02-24 |
| 2021-09-30 | $16.80M 10-Q · filed 2022-11-03 | $33.59M derived: sum of 2 quarters · filed 2022-11-03 | $50.39M 10-Q · filed 2022-11-03 | $67.18M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $16.80M 10-Q · filed 2022-08-04 | $33.59M 10-Q · filed 2022-08-04 | $50.38M derived: sum of 3 quarters · filed 2022-08-04 | $67.18M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $16.80M 10-Q · filed 2022-05-10 | $33.59M derived: sum of 2 quarters · filed 2022-05-10 | $50.38M derived: sum of 3 quarters · filed 2022-05-10 | $67.18M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $16.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $33.59M derived: sum of 2 quarters · filed 2022-02-24 | $50.38M derived: sum of 3 quarters · filed 2022-02-24 | $60.68M 10-K · filed 2022-02-24 |
| 2020-09-30 | $16.80M 10-Q · filed 2021-11-04 | $33.59M derived: sum of 2 quarters · filed 2021-11-04 | $43.88M 10-Q · filed 2021-11-04 | $47.57M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $16.80M 10-Q · filed 2021-08-05 | $27.09M 10-Q · filed 2021-08-05 | $30.78M derived: sum of 3 quarters · filed 2022-02-24 | $34.47M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $10.29M 10-Q · filed 2021-05-06 | $13.98M derived: sum of 2 quarters · filed 2022-02-24 | $17.67M derived: sum of 3 quarters · filed 2022-02-24 | $21.36M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $3.69M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $7.38M derived: sum of 2 quarters · filed 2022-02-24 | $11.06M derived: sum of 3 quarters · filed 2022-02-24 | $14.75M 10-K · filed 2022-02-24 |
| 2019-09-30 | $3.69M 10-Q · filed 2020-11-05 | $7.38M derived: sum of 2 quarters · filed 2020-11-05 | $11.06M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $3.69M 10-Q · filed 2020-08-05 | $7.38M 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $3.69M 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $109.83M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |